Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: A metanalysis

Breast Cancer Research and Treatment

Volumn 116, Issue 3, 2009, Pages 433-439

  Mauri, Davide ^a   Valachis, Antonis ^b   Polyzos, Ilias P ^c   Polyzos, Nikolaos P ^d   Kamposioras, Konstantinos ^a   Pesce, Lorenzo L ^e  

^a Oncology and Obstetrics and Gynaecology   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c PACMER: Dentistry and Oral Health   (United Kingdom)

^d PACMeR: Obstetrics and Gynaecology   (Greece)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adjuvant treatment; Bisphosphonates; Breast cancer; Clodronate; Early; Ibandronate; Osteonecrosis of the jaw; Pamidronate; Risedronate; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

BREAST CANCER; CANCER ADJUVANT THERAPY; HUMAN; INCIDENCE; JAW OSTEONECROSIS; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; ARTICLE; BONE NECROSIS; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; JAW DISEASE; RANDOMIZED CONTROLLED TRIAL;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS; INCIDENCE; JAW DISEASES; OSTEONECROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70349579947     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0432-z     Document Type: Review

References (38)

1. Pfeilschifter J, Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570-1593
2. Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311
3. Eastell R, Hannon RA, Cuzick J et al (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223
4. Mincey BA, Duh MS, Thomas SK et al (2006) Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7: 127-132
5. Cummings SR, Browner WS, Bauer D et al (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339:733-738
6. Hoff AO, Gagel RF (2005) Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park) 19:651-658
7. Brufsky A, Bosserman L, Caradonna R, Haley B, Jones M, Moore H, Dong M, Warsi G, Lacerna L, Perez E (2007) The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res Treat 106(Suppl. 1):S8 (Abstract 27)
8. De Boer R, Eidtmann H, Lluch A et al (2007) The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. Breast Cancer Res Treat 106(Suppl. 1):S36 (Abstract 501)
9. Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, Sereika SM, Vogel VG (2008) Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26:2644-2652
10. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE (2008) Prevention of anastrazole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342
11. Daubine F, Le Gall C, Gasser J et al (2007) Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99:322-330
12. van der Pluijm G, Vloedgraven H, van Beek E et al (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705
13. Boissier S, Ferreras M, Peyruchaud O et al (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949-2954
14. Senaratne SG, Pirianov G, Mansi JL et al (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468
15. Fromigue O, Kheddoumi N, Body JJ (2003) Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer 89:178-184
16. Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544
17. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic- Radicic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
18. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580-8587
19. Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in metaanalysis of sparse data. Stat Med 23:1351-1375
20. Egger M, Smith GD, Altman DG (2001) Systematic reviews in health care: meta-analysis in context. BMJ, London
21. Petitti DB (2000) Meta-analysis, decision analysis, and costeffectiveness analysis: methods for quantitative synthesis in medicine. Oxford University Press, New York
22. Mincey BA, Dentchev T, Sloan JA, Hines SL, Perez EA, Johnson DB, Schaefer PL, Liu H, Kahanic SP, Loprinzi CL (2008) N03CC-a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen. J Clin Oncol 26 (May 20 Suppl) [abstract 564]
23. Van Poznak C, Hannon R, Clack G, Campone M, Mackey JR, Apffelstaedt J, Eastell R (2008) Managing cancer treatmentinduced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE). Presented at San Antonio Breast Cancer Symposium (Abstract 1137)
24. Schenk N, Lombart A, Frassoladti A et al (2007) The E-ZOFAST trial: zoledronic acid (ZA) eff ectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let). Eur J Cancer 5(Suppl. 5):186-187 (Abstract 2008)
25. Shapiro CL, Halabi S, Gibson G, Weckstein DJ, Kirshner J, Sikov WM, Winer EP, Hudis CA, Isaacs C, Wecstein D, Schilsky RL, Paskett E (2008) Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who developed ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results of GALGB trial 79809. J Clin Oncol 26(May 20 Suppl) (abstract 512)
26. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26: 4739-4745
27. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E.G., Loprinzi CL, Atherton PJ, Carlson MD, Salim M, Perez EA (2008) N02C1: A phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer (BC). J Clin Oncol 26 (May 20 Suppl) [abstract 525]
28. Tevaarwerk A, Stewart JA, Love R, Binkley NC, Black S, Eickhoff J, Mulkerin DL (2007) Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women with breast cancer. J Clin Oncol 25 (Jun 20 18S) (Abstract 19558)
29. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C (2004) Tenyear follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656
30. Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C, Lindman H, Nordenskjöld B, Bergh J (2008) Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47(4):740-746
31. Powles T, Paterson S, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 8:R13
32. Coleman R, Thorpe H, Cameron D et al. (2006) Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-first safety data from the AZURE trial (BIG01/04) [poster] Presented at: 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 14-17 December 2006 (Abstr 2080)
33. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955-962
34. Fuleihan Gel-H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90:3209-3214
35. Vehmanen L, Saarto T, Risteli J, Risteli L, Blomqvist C, Elomaa I (2004) Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 87:181-188
36. Bryce CJ, Prior JC, Sill K, et al. (2002) Does short-term, intravenous, low dose clodronate, administered with adjuvant chemotherapy for premenopausal breast cancer reduce bone loss in the first year in patients? Proc Am Soc Clin Oncol 21 (Abstr. 270)
37. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19:2007-2011
38. Rosen LS, Gordon D, Antonio BS, Kaminski M (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377